Progenitor and Stem Cell Technologies and Therapies

Progenitor and stem cells have the ability to renew themselves and change into a variety of specialised types, making them ideal materials for therapy and regenerative medicine. Progenitor and stem cell technologies and therapies reviews the range of progenitor and stem cells available and their therapeutic application.Part one reviews basic principles for the culture of stem cells before discussing technologies for particular cell types. These include human embryonic, induced pluripotent, amniotic and placental, cord and multipotent stem cells. Part two discusses wider issues such as intellectual property, regulation and commercialisation of stem cell technologies and therapies. The final part of the book considers the therapeutic use of stem and progenitor cells. Chapters review the use of adipose tissue-derived stem cells, umbilical cord blood (UCB) stem cells, bone marrow, auditory and oral cavity stem cells. Other chapters cover the use of stem cells in therapies in various clinical areas, including lung, cartilage, urologic, nerve and cardiac repair.With its distinguished editor and international team of contributors, Progenitor and stem cell technologies and therapies is a standard reference for both those researching in cell and tissue biology and engineering as well as medical practitioners investigating the therapeutic use of this important technology.- Reviews the range of progenitor and stem cells available and outlines their therapeutic application- Examines the basic principles for the culture of stem cells before discussing technologies for particular cell types, including human embryonic, induced pluripotent, amniotic and placental, cord and multipotent stem cells- Includes a discussion of wider issues such as intellectual property, regulation and commercialisation of stem cell technologies and therapies

DedicationContributor contact detailsIntroductionPart I: Basic principles of stem cellsChapter 1: Basic principles for stem cell cultureAbstract:1.1 Introduction1.2 Understanding and standardization of in vitro culture systems1.3 Quality assurance1.4 Documentation1.5 Safety1.6 Legal, ethical and regulatory compliance1.7 Education and training1.8 Conclusion1.9 AcknowledgementChapter 2: Basic principles of human embryonic stem cellsAbstract:2.1 Introduction: biological properties of human embryonic stem cells (hESC)2.2 Historical overview2.3 Human embryonic stem cells (hESC) in therapy - current status and strategies for the future2.4 Human embryonic stem cells (hESC) in drug discovery - current status and strategies for the future2.5 Specific mutation-carrying (SMC) human embryonic stem cells (hESC)2.6 Human embryonic stem cells (hESC) utilization, the next step2.7 ConclusionChapter 3: Basic principles in generating induced pluripotent stem cellsAbstract:3.1 Introduction3.2 Evolution of reprogramming and the birth of induced pluripotency3.3 Current methods for induced reprogramming3.4 Conclusions and future prospectsChapter 4: Basic principles of amniotic fluid and placenta stem cellsAbstract:4.1 Introduction4.2 Amniotic fluid and placenta in developmental biology4.3 Isolation and characterization of progenitor cells4.4 Differentiation of amniotic fluid- and placenta-derived progenitor cells4.5 In vivo behavior of amniotic fluid stem cells4.6 Amniotic fluid and placenta for cell therapy4.7 Conclusion4.8 AcknowledgmentChapter 5: Basic principles of cord blood stem cellsAbstract:5.1 Introduction: history of cord blood stem cell technology5.2 Cord blood collection, processing and storage5.3 Public and private cord blood banking5.4 Cord blood haemopoietic stem cell transplantation5.5 Cord blood mesenchymal stem cells5.6 Current research and future developments5.7 Cord blood transfusion5.8 ConclusionChapter 6: Basic principles of multipotent stem cellsAbstract:6.1 Introduction6.2 Hematopoietic stem cells (HSC)6.3 Mesenchymal stem cells (MSC)6.4 Adult stem cells with broader potential6.5 In vitro and in vivo differentiation potential of multipotent adult progenitor cells (MAPC)6.6 Immunomodulatory properties of multipotent adult progenitor cells (MAPC)6.7 ConclusionPart II: Enabling cell therapyChapter 7: Intellectual property claims to stem cell technologies: research, clinical testing and product salesAbstract:7.1 Introduction7.2 International overview of patent laws and stem cell policies7.3 Introduction to the international stem cell patent landscape7.4 Human embryonic stem cell patents7.5 Advances in induced pluripotent stem cell patents (iPS cells)7.6 Models for access to, and management of, stem cell patents7.7 Conclusion7.8 AcknowledgmentsChapter 8: Regulatory considerations of stem and progenitor cell-based products: US Food and Drug AdministrationAbstract:8.1 Introduction8.2 Preparing the cellular component: chemistry, manufacturing and control considerations8.3 Preclinical testing: pharmacology/toxicology considerations8.4 Clinical trial considerations8.5 Combination products: considerations when combining stem/progenitor cells with other components8.6 Conclusion and future regulatory tools development8.7 AcknowledgmentsChapter 9: Cell therapy commercialisationAbstract:9.1 Introduction: cells as therapies9.2 The field to date9.3 Commercialisation9.4 Manufacturing9.5 Future trends9.6 Conclusion9.7 Acknowledgements9.8 Sources of further informationChapter 10: Stem cell tourismAbstract:10.1 Introduction10.2 Scope of the phenomenon10.3 Problems relating to stem cell tourism10.4 Responses10.5 Conclusion10.6 AcknowledgmentsPart III: Tissue-specific progenitor cellsChapter 11: Adipose tissue-derived stem cell biology and therapyAbstract:11.1 Introduction11.2 Characterization of adipose tissue-derived stromal cells11.